Pregnancy: There are no data from the use of Steglujan in pregnant women. There are limited data from the use of ertugliflozin in pregnant women. Based on results from animal studies, ertugliflozin may affect renal development and maturation (see Pharmacology: Toxicology: Preclinical safety data under Actions). Therefore, Steglujan should not be used during pregnancy.
Breast-feeding: There is no information regarding the presence of Steglujan or its individual components in human milk, the effects on the breast-fed infant, or the effects on milk production. No studies in lactating animals have been conducted with the combined components of Steglujan. Ertugliflozin and sitagliptin are present in the milk of lactating rats. Ertugliflozin caused effects in the offspring of lactating rats.
Pharmacologically mediated effects were observed in juvenile rats treated with ertugliflozin (see Pharmacology: Toxicology: Preclinical safety data under Actions). Since human kidney maturation occurs in utero and during the first 2 years of life when exposure from breast-feeding may occur, a risk to newborns/infants cannot be excluded. Steglujan should not be used during breast-feeding.
Fertility: The effect of Steglujan on fertility in humans has not been studied. No effects of ertugliflozin or sitagliptin on fertility were observed in animal studies (see Pharmacology: Toxicology: Preclinical safety data under Actions).